Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Induction of Th1 type response by DNA vaccinations with N, M, and E genes against SARS-CoV in mice

Huali Jin\textsuperscript{a}, Chong Xiao\textsuperscript{a}, Ze Chen\textsuperscript{b}, Youmin Kang\textsuperscript{a}, Yijie Ma\textsuperscript{a}, Kaichun Zhu\textsuperscript{c}, Qifa Xie\textsuperscript{a}, Yixian Tu\textsuperscript{c}, Yang Yu\textsuperscript{a}, Bin Wang\textsuperscript{a,c,*}

\textsuperscript{a} State Key Laboratory for Agro-Biotechnology, College of Biological Science, China Agricultural University, Beijing 100094, China
\textsuperscript{b} Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, China
\textsuperscript{c} Key Laboratory for Bioresources and Bioengineering and College of Life Science and Technology, Xinjiang University, Urumqi 830046, Xinjiang, China

Received 8 January 2005
Available online 25 January 2005

Abstract

Vaccination against the SARS-CoV infection is an attractive means to control the spread of viruses in public. In this study, we employed a DNA vaccine technology with the levamisole, our newly discovered chemical adjuvant, to generate Th1 type of response. To avoid the enhancement antibody issue, genes encoding the nucleocapsid, membrane, and envelope protein of SARS-CoV were cloned and their expressions in mammalian cells were determined. After the intramuscular introduction into animals, we observed that the constructs of the E, M, and N genes could induce high levels of specific antibodies, T cell proliferations, IFN-\(\gamma\), DTH responses, and in vivo cytotoxic T cells activities specifically against SARS-CoV antigens. The highest immune responses were generated by the construct encoding the nucleocapsid protein. The results suggest that the N, M, and E genes could be used as the targets to prevent SARS-CoV infection in the DNA vaccine development.

© 2005 Elsevier Inc. All rights reserved.

Keywords: SARS-CoV; Nucleocapsid protein; Membrane protein; Envelop protein; DNA vaccine; In vivo CTL; Th1 response

Severe acute respiratory syndrome (SARS) is a highly contagious disease, caused by a human coronavirus infection (SARS-CoV). The genome of SARS-CoV is a single-stranded positive-sense RNA including a 5'-cap and a 3'-polyadenylation structure, and encodes five major proteins typical of coronaviruses including the replicative polyproteins, the spike protein (S), the envelope protein (E), the membrane glycoprotein (M), and the nucleocapsid protein (N). To develop a safe and yet effective SARS vaccine is a new challenge for laboratories in the world. Spike protein has been indicated as the key protein to interact with the cell receptor in coronaviral family including the SARS-CoV [1]. Immunization with the spike protein or killed viral vaccine induces an enhancement antibody which accelerates subsequent infection of the feline coronavirus [2,3]. It suggests that the spike protein may not be a good candidate antigen used as vaccine development.

The M and E are two proteins playing an essential role in coronaviral particle assembling, and immune responses against these antigens should also be effective for inhibiting the viral infectivity or helping host cells to induce the production of protective IFN-\(\alpha\) [4,5].
As for the viral vaccine design, much attention has been focused on the induction of T cell responses, especially for the generation of cytotoxic T lymphocytes (CTL). Several studies have demonstrated that protective CTL responses were induced by the surface antigen of HBsAg virus [6,7]. However, more reports have shown that the nucleocapsid protein can be a good target to induce the protective CTL response in viruses, such as Ebola [8], influenza [9,10], and measles [11].

DNA vaccination has emerged as a practical technology for the generation of humoral and cellular immunity [12], and potentially used against some viral infections including human immunodeficiency virus [13], hepatitis B [14], and influenza [15].

Taking this into account, we examined the immune responses generated with DNA vaccines encoding the N, M, and E proteins of SARS-CoV into mice. All the three DNA vaccines induced potent Th1 polarized immune responses as well as specific antibodies in these animals. And the highest levels of humoral response and T cell proliferation activity were induced by the N gene construct. We also observed that in vivo CTL activities were successfully induced in mice by these DNA constructs.

Materials and methods

Animals. Female BALB/c mice 4–6 weeks old were purchased from Beijing Vital Laboratory Animal Technology (Beijing, China), randomly divided into groups at 10 per group, and received pathogen-free water and food for maintenance.

Virus isolation. A 35-year-old female patient was hospitalized and confirmed with diagnosis as infected with SARS-CoV. The SARS-CoV isolation was established by infecting Vero cells with the filtered stool sample from this patient under BSL-3 condition. Cytopathic effects were observed after 3-day cultures. cDNA was generated from the RNA isolated from the supernatant of the culture and used for the sequence analysis to confirm its SARS-CoV identity.

Plasmid constructs for immunization. All DNA vaccine constructs, encoding the E protein, the M glycoprotein, and the N protein of SARS-CoV, were obtained as follows: these genes were amplified from the cDNA by PCR amplifications using each set of specific primers, respectively. For the N gene, the upstream primer is 5'-AA-GAATTCGCCATTGCTGTAATAAGGCCCA-3' and the downstream one is 5'-AAATCATTGTTATATGCCATGGTGGATTG AATIC-3'; for the M gene, the upstream primer is 5'-AA-GAATTCGCCATTGCTGTAATAAGGCCCA-3' and the downstream one is 5'-AAATCATTGTTATATGCCATGGTGGATTG AATIC-3'; for the E gene, the upstream primer is 5'-AA-GAATTCGCCATTGCTGTAATAAGGCCCA-3' and the downstream one is 5'-AAATCATTGTTATATGCCATGGTGGATTG AATIC-3'. The three constructs were transfected into HeLa cells using the Lipofectamine according to the manufacturer's instruction (Invitrogen, CA, USA), respectively. Each total cellular RNA was extracted from the harvested cells using an extraction kit (Sangon, Shanghai, China) 24 h after the transfection. The cDNA was amplified by PCR with each pair of SARS-CoV-specific primers described above for 30 cycles (94 °C for 30 s, 55 °C for 30 s, and 72 °C for 30 s) and with an extension for 7 min at 72 °C in the last cycle. The PCR products were loaded on the 1.5% agarose gel and visualized under a 302 nm UV light.

Immunizations. For immunization, the DNA constructs were mixed with 1% levamisole (LMS) as an adjuvant for the final injection according to our previous study [17]. Each mouse was injected with 100 μg/100 μl DNA vaccine intramuscularly twice at a biweekly interval. Mice sera were collected regularly on day 0, 14, 28, 42, and 56, and stored at –20 °C for later use.

Detection of anti-SARS-CoV antibody. Serum anti-SARS-CoV antibody levels were assayed by enzyme-linked immunosorbent assay (ELISA) [18]. Ninety-six wells of microtiter plates were coated with 2 μg/ml of a chemically killed SARS-CoV antigen per well diluted in 100 μl of 0.05 M bicarbonate buffers (pH 9.6) at 4 °C overnight. Following the blocking of each well with 3% BSA-PBST at 37 °C for 1 h, the mouse serum with a serial dilution was added to each well and incubated at 37 °C for 1 h. A secondary goat anti-mouse antibody conjugated with horseradish peroxidase (Sigma, St. Louis, IL) at 1:1000 was added into each well and incubated at 37 °C for 1 h. To develop the ELISA, 10 mg TMB tablet (Sigma, St. Louis, IL) was dissolved in 1 ml of 0.025 M phosphate–citrate buffer and 50 μl of the resulting solution was added to each well. The reaction was stopped by addition of 0.2 M H2SO4 and the resulting optical density (OD) [18]. Ninety-six wells of microtiter plates were coated with 2 μg/ml of a chemically killed SARS-CoV antigen per well diluted in 100 μl of 0.05 M bicarbonate buffers (pH 9.6) at 4 °C overnight. Following the blocking of each well with 3% BSA-PBST at 37 °C for 1 h, the mouse serum with a serial dilution was added to each well and incubated at 37 °C for 1 h. A secondary goat anti-mouse antibody conjugated with horseradish peroxidase (Sigma, St. Louis, IL) at 1:1000 was added into each well and incubated at 37 °C for 1 h. To develop the ELISA, 10 mg TMB tablet (Sigma, St. Louis, IL) was dissolved in 1 ml of 0.025 M phosphate–citrate buffer and 50 μl of the resulting solution was added to each well. The reaction was stopped by addition of 0.2 M H2SO4 and the resulting optical density (OD) at 450/620 nm was analyzed with a plate reader (Magellan, Tecan Austria GmbH). Titre values were assigned as the highest dilution at which the optical density was 2 SDs higher than the OD produced by the serum of pre-immune mice at equivalent dilution.

Cell proliferation activity. On the 14th day after the second injection, the mice were sacrificed and single-cell suspension was prepared from spleens for each group as described previously [17]. The splenocytes were cultured in triplicate in 96-well microtiter plates at 5 × 10^3 cells per well in RPMI-10. The cultures were, respectively, stimulated for 24 h with each of the following: 5 μg/ml Con A (positive control), 2 μg/ml of the chemically killed SARS-CoV as the specific antigen, 2 μg/ml BSA (irrelevant antigen), or none (negative control). The cells were incubated at 37 °C and 5% CO2 for 48 h. The colorimetric reaction was performed according to “Cell Titer 96 Aqueous Non-Radioactive Cell Proliferation Assay” protocol (Promega, USA). Briefly, the cells were mixed with a mixture of MTS/PHS (20 μl each well) and further cultured for 4 h. The OD value was quantitatively read by absorbance at 490 nm with the plate reader (Magellan, Tecan Austria GmbH).

The stimulation indexes (SI) were determined by mean OD492 reading of triplicate antigen containing wells divided by mean OD492 reading of triplicate wells without antigen.
Antigen-specific DTH. Five mice from each group were tested for DTH response. Seven days after the second immunization, all mice were challenged with the chemically killed SARS-CoV in the right footpad and also received injections with saline solution at the left footpad as the control. The thickness of the footpad was measured at 24, 48, and 72 h later with an engineer’s micrometer.

In vivo CTL assay. In vivo cytotoxicity assay has been recently documented [19,20]. Briefly, to prepare target cells for the detection of in vivo cytotoxic activity, splenocytes were isolated from naïve BALB/c spleen after erythrocytes were removed. The single suspension cells were then washed and equally split into two parts, one of which was pulsed with the chemically killed SARS-CoV (50 μg/ml) at 37°C for 4 h and labeled with a high concentration of CFSE (2.5 μM, Molecular Probe, Portland, USA) designated as the CFSE<sup>high</sup> cells; while the other, as a control target, was only labeled with a low concentration of CFSE (0.25 μM) designated as the CFSE<sup>low</sup> cells. The two populations of cells were mixed together and injected intravenously at 2 × 10<sup>7</sup> cells into each mouse, which was previously immunized with E, M, N or control DNA constructs 7 days earlier. The mouse was sacrificed 4 h later to isolate lymph nodes. Cell suspensions from the lymph nodes were analyzed on a FACSCalibur analyzer (BD Biosciences, Mountain View, CA), and each population was detected via its differential CFSE fluorescent intensities. To calculate specific lysis, the following formula was used: ratio = (percentage CFSE<sup>low</sup>/percentage CFSE<sup>high</sup>)/(1 - (ratio unprimed/ratio primed)) × 100.

Cytokine assay. Relative amounts of cytokine levels were determined by semi-quantitative RT-PCR with a known amount of competitor, pQRS, as previously described [21]. An extraction kit (Sangon, Shanghai, China) was used to extract total RNA. The cDNA was synthesized by AMV reverse transcriptase and oligo(dT)18 primer. Each PCR was optimized with specific primers for the housekeeping or cytokine genes as described previously [17]. The amounts of specific competitor products of each reaction were assessed from scanned images of ethidium bromide-stained gels using Bio-Rad Image software (Quantity One 4.2.0). The total volume (intensity/area) of the specific product was determined and the statistical analysis was performed.

Statistical analysis. Statistical analysis was performed using Student’s t test, one-sided. Differences were considered statistically significant with p < 0.05.

Results

Expression of DNA constructs in HeLa cells

The identifications of the three constructs were analyzed by restriction digests and further confirmed by the sequence analysis (data not shown).

In order to confirm that the DNA constructs, pcD3d/E, pcD3d/M, and pcD3d/N, can express the E, M, and N proteins in the eukaryotic systems, each construct was transfected into 80% of confluent HeLa cells. The total RNA was extracted from the cells 24 h after the transfection and used to perform RT-PCR assays to detect the presence of the E, M, and N mRNAs with each pair of their specific primers. The target bands were observed from the cDNA transfected with these constructs, whereas no band with a similar size was detected from the pcD3d vector control transfected cells (Fig. 1). This result suggests that the three DNA constructs encoding the E, M, and N proteins can be successfully expressed in eukaryotic cells.

Generation of specific IgG in mice

To examine the humoral responses in mice, the levels of anti-SARS-CoV-specific antibodies of the mice immunized with pcD3d/E, pcD3d/M, and pcD3d/N, respectively, were determined by ELISA. Sera from day 14, 28, 42, and 56 were determined with the titers of specific IgG and shown in Fig. 2. All three constructs induced significantly higher levels of SARS-CoV-specific antibodies than that of the control group immunized with pcD3d vector. Moreover, among all inoculations, pcD3d/N induced the highest specific antibody titers against SARS-CoV.

T cell proliferation after DNA vaccine immunization

To determine the T cell proliferative response, single suspension of splenocytes was prepared from the mice spleen 14 days after the second immunization to perform the T cell proliferation assay. Fig. 3 shows that the highest stimulation indexes are achieved in the T cells isolated from spleens (Fig. 3A) and lymph nodes (Fig. 3B) of mice injected with pcD3d/N. The levels of proliferative responses of the mice immunized with the pcD3d/E and pcD3d/M are significantly higher than those of animals immunized with the pcD3d vector control.
**SARS-CoV-dependent DTH responses**

Since DTH is a reflection of antigen-specific T cell activation and proliferation in vivo from the antigen-sensitized animal reacting on the site challenged antigen, we next evaluated whether the SARS-CoV-dependent DTH could also be induced by the three DNA vaccines. On the 7th day after the second immunization, each group of mice was challenged with the chemically killed SARS-CoV on their right footpads, and saline solution on the left footpads as the negative control. The thickness of footpad was measured at 24, 48, and 72 h after challenging. From Table 1, we observed that the group of mice injected with the pcD3d/N showed the highest level of DTH, followed by the groups immunized with the pcD3d/M and pcD3d/E constructs.

**In vivo CTL**

Specific CTL activity has been demonstrated as an important factor to control viral infections. Previously many studies to access the CTL activity were performed in in vitro system, which may not directly reflect the situation in vivo. To detect the presence of anti-SARS-CoV-specific CTL in vivo, we have adopted the method previously documented [19,20]. After the target splenocytes differential labeled with CSFE were transferred into immunized or control mouse intravenously, specific antigen-labeled target cells were killed while the antigen unlabeled target would have survived. Fig. 4 shows that the degree of specific lysis is achieved in target cells isolated from the lymph node 4 h after the transfer into the immunized syngeneic host. The specific lysis of target cells at 50.6% (Fig. 4E) was observed in the mice immunized with the pcD3d/N construct, at 17% with those injected with the pcD3d/M construct (Fig. 4D), and at 5.6% with the group injected with the pcD3d/E construct (Fig. 4C). These data suggest that the mice vaccinated with the N construct produce the highest of CTL activities in vivo, which can be further concluded from the previous results that the N gene contains the more immunogenetic regions for T and B cell stimulations.

**Th1 and Th2 cytokine mRNA levels in mice**

Having demonstrated a better immunogenicity generated from the N gene, the profile of cytokines may lead to understand such significance. To measure the relative level of cytokines, all RNA samples were competed with the same amount of a competitor, pQRS, at 150 pg/ml [21], which showed the expression of housekeeping gene,
Memory during the priming. This was also consistent with previous observation of the protective immunity [26,27]. Furthermore, the administration with DNAs generated a lower level of IL-10 (Fig. 5), suggesting that a locomotor’s role of DNA initiated Th1 polarized immunity.

For vaccine design, much attention has been focused on the induction of T cell responses especially of the antigen-specific CTL. Several studies have found that the nucleocapsid protein could induce CTL responses in the cases of the human Hantaan virus [28], the lethal coronavirus peritonitis virus [29], and SHIV-1 [30]. Recently, Zhu et al. [31] have found that a DNA construct based on the pcD3d vector could successfully induce SARS-CoV N protein-specific immune responses in a manner of inducing high antibody titers and CTL responses. Kim [32] has demonstrated that the vaccination with N DNA vaccine could successfully induce a SARS-CoV antigen-specific CD8+ T cell response and distinctly reduce the titer of recombinant vaccinia virus expressing SARS-CoV N protein after the challenge and that the co-expression of calreticulin (CRT), a 46 kDa Ca2+-binding protein, with N gene could enhance its ability to protect against viral challenges. In the present study, it was consistent with their work that the N protein construct could induce the highest SARS-specific IgG, T cell proliferation, and in vivo CTL response (lysis rate of 50.6%) compared with M protein gene (lysis rate of 17%) and E protein gene (lysis rate of 5.6%) (Fig. 4). Furthermore, the highest Th1 type response based on expressions of the IFN-γ and IL-2 was also induced by N protein. However, the higher level of immune responses generated by the pcD3d/N vaccine may be due to more epitopes in the N nucleocapsid protein since it contains 422 amino acid residues, while the M protein has 220 amino acids. In addition, the differential concentrations of each antigen presented in the killed SARS-CoV preparation could have also contributed to the differences.

Specific CTL activity has been demonstrated as an important factor to confront virus infections. It has been previously documented that monkeys vaccinated with
the DNA vaccine encoding the Gag protein, the nuclear protein, can induce specific CTLs in monkeys, and thus confer partial protection against the challenge with the SHIV (simian/human immunodeficiency virus) [30]. We have accessed the CTL in in vivo situation with the three DNA vaccines tested in this study and indicated that high levels of in CTL can be generated against the SARS-CoV-labeled target cells. Whether the in vivo CTL could control the SARS-CoV infection is needed for further investigation.
It is well known that the protective immunity against viral infections is associated with the induction of Th1 immune response. Production of the antigen-specific IL-2 and IFN-γ in the splenocytes was all augmented significantly by vaccinations of these three DNA constructs compared with the vector or the naïve control. The group receiving the immunization of the pcOD3d/N induced the highest levels for both IL-2 and IFN-γ shown in Fig. 5, which is consistent with the highest levels of both antigen-specific T cell activity shown in Fig. 3 and DTH response in mice shown in Table 1.

In summary, the administrations with all three SARS-CoV DNA vaccines in our study were able to induce high levels of the antigen-specific IgG antibody, the T cell proliferation, IFN-γ, DTH, and in vivo CTL responses. It suggests that the Th1 type of response is induced by the three structural genes of SARS-CoV in DNA vaccinations, which may lead to a desirable means when a therapeutic approach against SARS-CoV infection is considered.

Acknowledgments

This work was supported in part by the special research fund to B.W. provided by CAU. We thank Dr. Jane Q.L. Yu, Mr. Qinghong Zhu, and Mr. Zhonghuai He for their assistance of the work.

References

[1] W. Li, M.J. Moore, N. Vasilieva, J. Sui, S.K. Wong, M.A. Berne, M. Somasundaran, J.L. Sullivan, K. Luzuriaga, T.C. Greenough, H. Choe, M. Farzan, Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus, Nature 426 (2003) 450–454.

[2] R.C. Weiss, F.W. Scott, Antibody-mediated enhancement of disease in feline infectious peritonitis: Comparisons with dengue hemorrhagic fever, Comp. Immunol. Microbiol. Infect. Dis. 4 (1981) 175–189.

[3] H. Vennema, R.J. de Groot, D.A. Harbour, M. Dalderup, T. Gruffydd-Jones, M.C. Horzinek, W.J. Spaan, Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization, J. Virol. 64 (1990) 1407–1409.

[4] B. Charley, H. Laude, Induction of alpha interferon by transmissible gastroenteritis coronavirus: Role of transmembrane glycoprotein E1, J. Virol. 62 (1988) 8–11.

[5] H. Laude, J. Gelfi, L. Lavenant, B. Charley, Single amino acid changes in the viral glycoprotein M affect induction of alpha interferon by the coronavirus transmissible gastroenteritis virus, J. Virol. 66 (1992) 743–749.

[6] D. Loirat, F.A. Lemonnier, M.-L. Michel, Multiepitopic HLA-A*0201-restricted immune response against hepatitis B surface antigen after DNA-based immunization, J. Immunol. 165 (2000) 4748–4755.

[7] I. Kiszka, D. Kmiecik, J. Gzl, T. Naito, E. Bolest, A. Sieron, S.P. Singh, A. Srinivasan, G. Trinchieri, Y. Kaneko, D. Koobor, Effect of the V3 loop deletion of envelope glycoprotein on cellular responses and protection against challenge with recombinant vaccinia virus expressing gp160 of primary human immunodeficiency virus type 1 isolates, J. Virol. 76 (2002) 4222–4232.

[8] J.A. Wilson, M.K. Hart, Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein, J. Virol. 75 (2001) 2660–2664.

[9] Z. Chen, K. Matsuo, H. Asanuma, H. Takahashi, I. Iwasaki, Y. Suzuki, C. Aizawa, T. Kurata, S. Tamura, Enhanced protection against a lethal influenza virus challenge by immunization with both hemagglutinin- and neuraminidase-expressing DNAs, Vaccine 17 (1999) 653–659.

[10] Z. Chen, T. Yoshikawa, S.-e. Kadowaki, Y. Hagiwara, K. Matsuo, H. Asanuma, C. Aizawa, T. Kurata, S.-i. Tamura, Protection and antibody responses in different strains of mouse immunized with plasmid DNAs encoding influenza virus haemagglutinin, neuraminidase and nucleoprotein, J. Gen. Virol. 80 (1999) 2559–2564.

[11] E.B. Schadeck, C.D. Partidos, A.R. Fooks, O.E. Obeid, G.W. Wilkinson, J.R. Stephenson, M.W. Steward, CTL epitopes identified with a defective recombinant adenovirus expressing measles virus nucleoprotein and evaluation of their protective capacity in mice, Virus Res. 65 (1999) 75–86.

[12] S. Gurunathan, D.M. Klisman, R.A. Seder, DNA vaccines: Immunology, application, and optimization*, Annu. Rev. Immunol. 18 (2000) 927–974.

[13] D. O’Hagan, M. Singh, M. Ugozoli, C. Wild, S. Barnett, M. Chen, M. Schaefer, B. Doe, G.R. Otten, J.B. Ulmer, Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines, J. Virol. 75 (2001) 9037–9043.

[14] R. Schirmbeck, X. Zheng, M. Roggendorf, M. Geissler, F.V. Chisari, J. Reimann, M. Lu, Targeting murine immune responses to selected T cell- or antibody-defined determinants of the hepatitis B surface antigen by plasmid DNA vaccines encoding chimeric antigen, J. Immunol. 166 (2001) 1405–1413.

[15] R.G. Webster, E.F. Fynan, J.C. Santoro, H. Robinson, Protection of ferrets against influenza challenge with a DNA vaccine to the haemagglutinin, Vaccine 12 (1994) 1495–1498.

[16] J. Sambrook, E. Fritsch, T. Maniatis, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York, 1989.
[17] H. Jin, Y. Li, Z. Ma, F. Zhang, Q. Xie, D. Gu, B. Wang, Effect of chemical adjuvants on DNA vaccination, Vaccine 22 (2004) 2925–2935.

[18] A. Biragyn, I.M. Belyakov, Y.-H. Chow, D.S. Dimitrov, J.A. Berzofsky, L.W. Kwak, DNA vaccines encoding human immunodeficiency virus-1 glycoprotein 120 fusions with proinflammatory chemoattractants induce systemic and mucosal immune responses, Blood 100 (2002) 1153–1159.

[19] S. Oehen, K. Brduscha-Riem, Differentiation of naive CTL to effector and memory CTL: Correlation of effector function with phenotype and cell division, J. Immunol. 161 (1998) 5338–5346.

[20] R.M. Coles, S.N. Mueller, W.R. Heath, F.R. Carbone, A.G. Brooks, Progression of armed CTL from draining lymph node to spleen shortly after localized infection with herpes simplex virus 1, J. Immunol. 168 (2002) 834–838.

[21] S.L. Reiner, S. Zheng, D.B. Corry, R.M. Locksley, Constructing polycompetitor cDNAs for quantitative PCR, J. Immunol. Methods 165 (1993) 37–46.

[22] J.-P. Sauzet, B.-L. Perlaza, K. Brahimi, P. Daubersies, P. Druihle, DNA immunization by Plasmodium falciparum liver-stage antigen3 induces protection against Plasmodium yoelii sporozoite challenge, Infect. Immun. 69 (2001) 1202–1206.

[23] M. Sedegah, W. Weiss, J.B. Sacchi Jr., Y. Charoenvit, R. Hedstrom, K. Gowda, V.F. Majam, J. Tine, S. Kumar, P. Hobart, S.L. Hoffman, Improving protective immunity induced by DNA-based immunization: Priming with antigen and GM-CSF-encoding plasmid DNA and boosting with antigen-expressing recombinant poxvirus, J. Immunol. 164 (2000) 5905–5912.

[24] J.B. Ulmer, J.J. Donnelly, S.E. Parker, G.H. Rhodes, P.L. Felgner, V.J. Dwarki, S.H. Gromkowski, R.R. Deck, C.M. DeWitt, A. Friedman, Heterologous protection against influenza by injection of DNA encoding a viral protein, Science 259 (1993) 1745–1749.

[25] H.L. Robinson, C.A. Torres, DNA vaccines, Semin. Immunol. 9 (1997) 271–283.

[26] S.J. Dunachie, A.V.S. Hill, Prime-boost strategies for malaria vaccine development, J. Exp. Biol. 206 (2003) 3771–3779.

[27] H. McShane, R. Brookes, S.C. Gilbert, A.V.S. Hill, Enhanced immunogenicity of CD4+ T-cell responses and protective efficacy of a DNA-modified vaccinia virus ankara prime-boost vaccination regimen for murine tuberculosis, Infect. Immun. 69 (2001) 681–686.

[28] H.L. Van Epps, C.S. Schmaljohn, F.A. Ennis, Human memory cytotoxic T-lymphocyte (CTL) responses to Hantaan virus infection: Identification of virus-specific and cross-reactive CD8+ CTL epitopes on nucleocapsid protein, J. Virol. 73 (1999) 5301–5308.

[29] H.L. Glansbeek, B.L. Haagmans, E.G. te Lintelo, H.F. Egberink, V. Duquesne, A. Aubert, M.C. Horzinek, P.J.M. Rottier, Adverse effects of feline IL-12 during DNA vaccination against feline infectious peritonitis virus, J. Gen. Virol. 83 (2002) 1–10.

[30] W. Akahata, E. Ido, H. Akiyama, H. Uesaka, Y. Enose, R. Horiuchi, T. Kuwata, T. Goto, H. Takahashi, M. Hayami, DNA vaccination of macaques by a full-genome simian/human immunodeficiency virus type 1 plasmid chimera that produces non-infectious virus particles, J. Gen. Virol. 84 (2003) 2237–2244.

[31] M.S. Zhu, Y. Pan, H.Q. Chen, Y. Shen, X.C. Wang, Y.J. Sun, K.H. Tao, Induction of SARS-nucleoprotein-specific immune response by use of DNA vaccine, Immunol. Lett. 92 (2004) 237–243.

[32] T.W. Kim, J.H. Lee, C.-F. Hung, S. Peng, R. Roden, M.-C. Wang, R. Viscidi, Y.-C. Tsai, L. He, P.-J. Chen, D.A.K. Boyd, T.C. Wu, Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus, J. Virol. 78 (2004) 4638–4645.